Introduction {#jcmm12853-sec-0001}
============

Digestive tract cancers (DTCs), well known as the most common malignant tumours globally, include oesophageal, gastric and colorectal cancers [1](#jcmm12853-bib-0001){ref-type="ref"}, [2](#jcmm12853-bib-0002){ref-type="ref"}, [3](#jcmm12853-bib-0003){ref-type="ref"}, [4](#jcmm12853-bib-0004){ref-type="ref"}. Data from *Global Cancer Statistics*, 2012 [1](#jcmm12853-bib-0001){ref-type="ref"} suggest that DTC has contributed to an enormous burden on society today. Actually, colorectal cancer is confirmed as the third most frequently diagnosed cancer in males and the second in females. Both the incidence rates of gastric cancer and oesophageal cancer keep the highest in Eastern Asia. Despite of the updating advances in surgery and chemotherapy, DTC remains the high‐mortality disease, even the leading cause of cancer‐related death [4](#jcmm12853-bib-0004){ref-type="ref"}. As generally accepted, the mechanism of the digestive tract tumorigenesis is a comprehensive combination of multiple risk factors including environmental conditions, dietary habits and genetic predispositions [5](#jcmm12853-bib-0005){ref-type="ref"}, [6](#jcmm12853-bib-0006){ref-type="ref"}, [7](#jcmm12853-bib-0007){ref-type="ref"}. Among these, metabolism‐associated genetic susceptibility has become an important focus. As a member of the CYP1 family, Cytochrome P4501A1 (CYP1A1) regulates the metabolism of many endogenous and exogenous carcinogens [3](#jcmm12853-bib-0003){ref-type="ref"}, [8](#jcmm12853-bib-0008){ref-type="ref"}, [9](#jcmm12853-bib-0009){ref-type="ref"}. *CYP1A1*, as its protein‐coding gene, is located on Chr15q22\~q14, encoding aryl hydrocarbon hydroxylase. Aryl hydrocarbon hydroxylase is active in metabolizing some pro‐carcinogens, particularly the polycyclic aromatic hydrocarbons (PAHs), into intermediates. The intermediate substitutes may contribute to carcinogenesis eventually if bind to DNA and form adducts [10](#jcmm12853-bib-0010){ref-type="ref"}, [11](#jcmm12853-bib-0011){ref-type="ref"}, [12](#jcmm12853-bib-0012){ref-type="ref"}, [13](#jcmm12853-bib-0013){ref-type="ref"}, [14](#jcmm12853-bib-0014){ref-type="ref"}, [15](#jcmm12853-bib-0015){ref-type="ref"}.

*CYP1A1* gene consists of many single nucleotide polymorphisms (SNPs). These diverse variants could break the initial physiological equilibrium between activation and detoxification of metabolic carcinogens by adjusting the quantity and function of such enzyme. The two functional polymorphisms in *CYP1A1*gene, *MspI* (T \>C, occurring in the noncoding 3′‐flanking region, rs4646903) and *Ile462Val* (A\>G, found at codon 462 in exon 7, rs1048943), may associate with the risk of DTC by the mechanism above [9](#jcmm12853-bib-0009){ref-type="ref"}.

Many studies have been carried out to examine the association between the two polymorphisms of *CYP1A1* and risk of many cancers [9](#jcmm12853-bib-0009){ref-type="ref"}. However, because of different subject selections, the results were inconsistent. In addition, the relationship for DTC risk has been only explored in Chinese population by Liu *et al*. [14](#jcmm12853-bib-0014){ref-type="ref"}. Hence, to further explore that association in the whole of humanity and clarify the former results, we conduct this meta‐analysis with more eligible studies.

Materials and methods {#jcmm12853-sec-0002}
=====================

Literature search strategy {#jcmm12853-sec-0003}
--------------------------

The published case--control studies about the associations between the *CYP1A1* polymorphisms and DTC were searched manually on PubMed and Embase Database up to 30th September, 2015. The search was limited to English language papers, using the key words '(*CYP1A1* or *P4501A1* or *MspI* or exon7 or *Ile/Val* or cytochrome)' and 'polymorphism' and '(colorectal cancer or gastric cancer or oesophageal cancer)'. And the following criteria were established: (*i*) case--control studies, (*ii*) exploring the association between *MspI* or *Ile/Val* polymorphism and DTC, (*iii*) DTC confirmed histologically or pathologically, (*iv*) providing sufficient data to calculate the odds ratio (OR) with its 95% confidence interval (CI) and *P*‐value. The exclusion criteria were as follows: (*i*) a case report or a review, (*ii*) no sufficient genotype frequency, (*iii*) a duplicated publication [10](#jcmm12853-bib-0010){ref-type="ref"}, [11](#jcmm12853-bib-0011){ref-type="ref"}, [12](#jcmm12853-bib-0012){ref-type="ref"}, [13](#jcmm12853-bib-0013){ref-type="ref"}, [14](#jcmm12853-bib-0014){ref-type="ref"}, [15](#jcmm12853-bib-0015){ref-type="ref"}.

Data extraction {#jcmm12853-sec-0004}
---------------

Based on the inclusion criteria listed above, two authors independently extracted data from all qualified publications. Controversies were eliminated through discussion with another investigator. Following data were collected: first author' s name, year of publication, cancer type, country and ethnicity of population, genotyping method, source of controls, number of cases and controls with different genotypes, adjusted OR and 95% CI and adjustment of variables if available and Hardy--Weinberg equilibrium (HWE) [14](#jcmm12853-bib-0014){ref-type="ref"}, [15](#jcmm12853-bib-0015){ref-type="ref"} (See in Tables [1](#jcmm12853-tbl-0001){ref-type="table-wrap"} and [2](#jcmm12853-tbl-0002){ref-type="table-wrap"}).

###### 

Characteristics of *CYP1A1 MspI* polymorphism included in the meta‐analysis

                       Year   Ethnicity   Source   Case   Control   Method   Sample size   *P* for HWE   OR 95% CI[a](#jcmm12853-note-0002){ref-type="fn"}   Adjustment of variables                                                                                    
  -------------------- ------ ----------- -------- ------ --------- -------- ------------- ------------- --------------------------------------------------- ------------------------- ---- --------------- ------- ----------- ------------------- ------------------- --------------------------------
  *MspI*                                                                                                                                                                                                                                                                
  EC                                                                                                                                                                                                                                                                    
  Jain *et al*.        2007   Asian       PB       171    59        83       19            201           79                                                  99                        23   PCR             ≥300    0.629       1.1 (0.71--1.7)     1.1 (0.55--2.2)     Age, gender, smoking, drinking
  Malik *et al*.       2010   Asian       PB       135    76        52       7             195           95                                                  88                        12   MLPA            ≥300    0.361       0.72 (0.45--1.14)   0.70 (0.26--1.87)   Age, gender
  GC                                                                                                                                                                                                                                                                    
  Ma *et al*.          2006   Asian       PB       60     26        27       7             57            26                                                  28                        3    PCR‐RFLP        \<300   0.423       --                  --                  --
  Malik *et al*.       2009   Asian       HB       108    60        46       2             195           95                                                  88                        12   PCR             ≥300    0.361       0.84 (0.52--1.37)   0.34 (0.07--1.60)   Age, gender
  Luo *et al*.         2011   Asian       PB       123    38        61       24            129           47                                                  54                        28   PCR‐RFLP        \<300   0.261       --                  --                  --
  Ghoshal *et al*.     2014   Asian       PB       88     41        36       11            170           78                                                  80                        12   PCR‐RFLP        \<300   0.370       --                  --                  --
  Darazy *et al*.      2011   Caucasian   PB       11     9         0        2             56            54                                                  1                         1    PCR‐RFLP        \<300   **0.000**   0.87 (0.5--1.5)     1.8 (0.7--4.4)      Age, gender
  CC                                                                                                                                                                                                                                                                    
  Sivaraman *et al*.   1994   Mixed       PB       43     23        10       10            47            23                                                  22                        2    PCR‐RFLP        \<300   0.508       --                  --                  --
  Ye *et al*.          2002   Caucasian   NR       41     35        6        0             82            73                                                  9                         0    PCR‐RFLP        \<300   0.871       --                  --                  --
  Talseth *et al*.     2006   Caucasian   NR       118    94        20       4             100           91                                                  9                         0    PCR‐RFLP        \<300   0.895       --                  --                  --
  Darazy *et al*.      2011   Caucasian   PB       46     42        2        2             56            54                                                  1                         1    PCR‐RFLP        \<300   **0.000**   --                  --                  --
  Saeed *et al*.       2013   Asian       HB       94     70        21       3             79            73                                                  6                         0    PCR‐RFLP        \<300   0.940       --                  --                  --
  Rudolph *et al*.     2011   German      PB       679    539       134      6             679           564                                                 102                       13   KASPar assays   ≥300    **0.007**   --                  --                  --

Significance of bold value: *P* \< 0.05 for HWE is considered as significant disequilibrium.

Adjusted. EC: oesophageal cancer; GC: gastric cancer; CC: colorectal cancer; HB: Hospital based; PB: Population based; NR: no record; HWE: Hardy--Weinberg equilibrium; PCR‐RFLP: polymerase chain reaction‐restriction fragment length polymorphism; PCR--ASO: PCR--allele specific oligonucleotide.
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###### 

Characteristics of *CYP1A1 Ile462Val* polymorphism included in the meta‐analysis

  Study                      Year   Ethnicity   Source   Case   Control   Method   Sample size   *P* for HWE   OR 95% CI[a](#jcmm12853-note-0003){ref-type="fn"}   Adjustment of variables                                                                                         
  -------------------------- ------ ----------- -------- ------ --------- -------- ------------- ------------- --------------------------------------------------- ------------------------- ---- ------------------- ------- ----------- ------------------- -------------------- ----------------------------------------------------------------------------
  *Ile462Val*                                                                                                                                                                                                                                                                      
  EC                                                                                                                                                                                                                                                                               
  Morita *et al*.            1997   Asian       HB       53     32        20       1             132           80                                                  49                        3    PCR                 \<300   0.355       --                  --                   --
  Nimura *et al*.            1997   Asian       HB       89     50        26       13            137           92                                                  38                        7    PTC‐150             \<300   0.518       --                  --                   --
  Hori *et al*.              1997   Asian       NR       101    62        37       2             428           275                                                 133                       20   nonRI‐SSCP          ≥300    0.752       --                  --                   --
  Lieshout *et al*.          1999   Caucasian   NR       34     26        8        0             247           207                                                 37                        3    PCR‐RFLP            \<300   0.665       --                  --                   --
  Wang *et al*.              2002   Asian       HB       127    25        58       44            101           31                                                  48                        22   PCR                 \<300   0.915       --                  --                   --
  Wu *et al*.                2002   Asian       HB       146    68        62       16            324           179                                                 127                       18   PCR‐RFLP            ≥300    0.762       1.34 (0.86--2.07)   2.48 (1.15--5.34)    Age, education, ethnicity, smoking, drinking, and areca consumption
  Wang *et al*.              2003   Asian       PB       62     30        28       4             38            20                                                  16                        2    PCR‐RFLP            \<300   0.870       --                  --                   --
  Wang *et al*.              2004   Asian       HB       127    21        56       50            101           31                                                  48                        22   PCR                 \<300   0.915       1.7 (0.83--3.58)    3.3 (1.49--7.61)     Tobacco smoking、alcohol drinking、FHEC
  Abbas *et al*.             2004   Caucasian   PB       79     61        9        9             130           101                                                 6                         23   PCR‐RFLP            \<300   **0.000**   2.63 (0.84--8.28)   --                   Age, sex
  Wang *et al*.              2012   Asian       PB       565    304       225      36            468           295                                                 154                       19   PCR                 ≥300    0.981                           --                   --
  Yun *et al*.               2013   Asian       PB       157    73        72       12            157           95                                                  50                        12   PCR‐RFLP            ≥300    0.348       2.05 (1.19--3.54)   1.12 (0.41--3.04)    Age, gender, smoking, drinking and FHC
  GC                                                                                                                                                                                                                                                                               
  Suzuki *et al*.            2004   Asian       HB       144    84        51       9             177           104                                                 65                        8    PCR                 ≥300    0.865                           --                   --
  Li *et al*.                2005   Asian       HB       102    53        27       22            62            35                                                  24                        3    PCR                 \<300   0.910       0.59 (0.26--1.34)   5.91 (1.28--27.24)   Age, sex, education, job, drinking, smoking
  Shen *et al*.              2005   Asian       PB       112    70        36       6             676           412                                                 226                       38   PCR‐RFLP            ≥300    0.639       0.9 (0.5--1.4)      0.7 (0.2--1.8)       Age, gender, living areas, FHC, drinking
  Agudo *et al*.             2006   Caucasian   PB       243    229       13       1             936           874                                                 62                        0    SNP500cd            ≥300    0.578       0.90 (0.48--1.68)   --                   Age, sex, centre, and date of blood extraction
  Kobayashi *et al*.         2009   Asian       HB       141    91        44       6             286           162                                                 109                       15   MassARRAY system    ≥300    0.832       0.79 (0.40--1.57)   2.01 (0.45--9.48)    *H. p* status, smoking, drink, FHGC, BMI, total food intake, JA membership
  CC                                                                                                                                                                                                                                                                               
  Sivaraman *et al*.         1994   Mixed       PB       43     32        9        2             47            33                                                  14                        0    PCR‐RFLP            \<300   0.487       --                  --                   --
  Kiss *et al*.              2000   Mixed       PB       163    119       41       3             163           132                                                 31                        0    PCR‐ASO             ≥300    0.407       --                  --                   --
  Slattery *et al*.          2004   Mixed       HB       1791   1632      148      11            2180          1997                                                171                       12   PCR                 ≥300    **0.001**   1.0 (0.7, 1.4)      1.5 (0.5, 4.9)       Age, sex
  Little *et al*.            2006   Caucasian   PB       251    235       16       0             396           372                                                 24                        0    PCR                 ≥300    0.824       1.31 (0.59--2.91)   --                   Age, sex, FHCC, aspirin use, use of other NSAIDs and physical activity
  Yeh *et al*.               2007   Asian       HB       717    400       228      89            729           410                                                 266                       53   PCR‐RFLP            ≥300    0.558       --                  --                   --
  Yoshida *et al*.           2007   Asian       NR       66     34        27       5             121           79                                                  37                        5    PCR‐RFLP            \<300   0.968       1.54 (0.78--3.04)   1.99 (0.41--9.63)    Age, gender, smoking habit
  Pereira Serafim *et al*.   2008   Mixed       PB       114    14        97       3             114           81                                                  33                        0    PCR‐RFLP            \<300   0.196       --                  --                   --
  Kobayashi *et al*.         2009   Asian       HB       105    65        32       8             225           125                                                 87                        13   Mass ARRAY system   ≥300    0.915       0.43 (0.171.06)     0.76 (0.144.13)      Smoking, drinking, FHCC, BMI, JA membership, and intake of other food
  Nisa *et al*.              2010   Asian       PB       685    418       231      36            778           461                                                 276                       41   PCR‐RFLP            ≥300    0.999       0.94 (0.75--1.17)   1.00 (0.62--1.62)    Age, sex, residence, smoking, drinking, BMI, job, physical activity, FHCC
  Cleary *et al*.            2010   Caucasian   PB       1160   1052      98       10            1288          1166                                                114                       8    Taq‐man             ≥300    **0.023**   0.95 (0.71, 1.27)   1.37 (0.53, 3.55)    Age, sex

Significance of bold value: *P* \< 0.05 for HWE is considered as significant disequilibrium.

Adjusted. EC: oesophageal cancer; GC: gastric cancer; CC: colorectal cancer; HB: Hospital based; PB: Population based; NR: no record; HWE: Hardy--Weinberg equilibrium; PCR‐RFLP: polymerase chain reaction‐restriction fragment length polymorphism; PCR--ASO: PCR--allele specific oligonucleotide; FHEC: family history of EC.
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Statistical analysis {#jcmm12853-sec-0005}
--------------------

The HWE in control group was assessed by Pearson\'s goodness‐of‐fit chi‐square test and *P* \< 0.05 was considered as significant disequilibrium. OR and 95% CI were calculated for *CYP1A1 MspI/Ile462Val* polymorphisms and DTC risk in each study. The pooled OR was also determined by the Z‐test (if *P* \< 0.05, then considered as significant). Stratified analyses by cancer type, source of controls, ethnicity, sample size and genotyping method were performed [9](#jcmm12853-bib-0009){ref-type="ref"}, [10](#jcmm12853-bib-0010){ref-type="ref"}, [11](#jcmm12853-bib-0011){ref-type="ref"}, [12](#jcmm12853-bib-0012){ref-type="ref"}, [13](#jcmm12853-bib-0013){ref-type="ref"}, [14](#jcmm12853-bib-0014){ref-type="ref"}, [15](#jcmm12853-bib-0015){ref-type="ref"}.The influence of study size of each evaluated publication on the results was assessed by the weight.

Heterogeneity in our meta‐analysis was assessed by the chi‐square‐based Q‐test and *I* ^2^. A fixed‐effects model (the Mantel--Haenszel method) was applied if *P* \> 0.05, which indicated no or little heterogeneity among eligible studies. Otherwise, the random‐effects model (Der Simonian and Laird method) was used. Galbraith graph was performed to explore the source of heterogeneity. Sensitivity analysis was tested to assess the stability of our results. The funnel plot was performed for potential publication bias. Funnel plot asymmetry was statistically assessed by Egger\'s linear regression test (publication bias exists if *P* \< 0.05). All statistical analyses were carried out by Stata software (version 12.0, StataCorp LP, College Station, TX, USA) [13](#jcmm12853-bib-0013){ref-type="ref"}, [14](#jcmm12853-bib-0014){ref-type="ref"}, [15](#jcmm12853-bib-0015){ref-type="ref"}.

Results {#jcmm12853-sec-0006}
=======

Characteristics of studies {#jcmm12853-sec-0007}
--------------------------

Totally 37 publications [16](#jcmm12853-bib-0016){ref-type="ref"}, [17](#jcmm12853-bib-0017){ref-type="ref"}, [18](#jcmm12853-bib-0018){ref-type="ref"}, [19](#jcmm12853-bib-0019){ref-type="ref"}, [20](#jcmm12853-bib-0020){ref-type="ref"}, [21](#jcmm12853-bib-0021){ref-type="ref"}, [22](#jcmm12853-bib-0022){ref-type="ref"}, [23](#jcmm12853-bib-0023){ref-type="ref"}, [24](#jcmm12853-bib-0024){ref-type="ref"}, [25](#jcmm12853-bib-0025){ref-type="ref"}, [26](#jcmm12853-bib-0026){ref-type="ref"}, [27](#jcmm12853-bib-0027){ref-type="ref"}, [28](#jcmm12853-bib-0028){ref-type="ref"}, [29](#jcmm12853-bib-0029){ref-type="ref"}, [30](#jcmm12853-bib-0030){ref-type="ref"}, [31](#jcmm12853-bib-0031){ref-type="ref"}, [32](#jcmm12853-bib-0032){ref-type="ref"}, [33](#jcmm12853-bib-0033){ref-type="ref"}, [34](#jcmm12853-bib-0034){ref-type="ref"}, [35](#jcmm12853-bib-0035){ref-type="ref"}, [36](#jcmm12853-bib-0036){ref-type="ref"}, [37](#jcmm12853-bib-0037){ref-type="ref"}, [38](#jcmm12853-bib-0038){ref-type="ref"}, [39](#jcmm12853-bib-0039){ref-type="ref"}, [40](#jcmm12853-bib-0040){ref-type="ref"}, [41](#jcmm12853-bib-0041){ref-type="ref"}, [42](#jcmm12853-bib-0042){ref-type="ref"}, [43](#jcmm12853-bib-0043){ref-type="ref"}, [44](#jcmm12853-bib-0044){ref-type="ref"}, [45](#jcmm12853-bib-0045){ref-type="ref"}, [46](#jcmm12853-bib-0046){ref-type="ref"}, [47](#jcmm12853-bib-0047){ref-type="ref"}, [48](#jcmm12853-bib-0048){ref-type="ref"}, [49](#jcmm12853-bib-0049){ref-type="ref"}, [50](#jcmm12853-bib-0050){ref-type="ref"}, [51](#jcmm12853-bib-0051){ref-type="ref"}, [52](#jcmm12853-bib-0052){ref-type="ref"} containing 39 studies (6 pieces not consistent with HWE were also included), which investigated the relationship between *CYP1A1* (*MspI* rs4646903 or *Ile/Val* rs1048943) polymorphisms and DTC risk, were included in the present meta‐analysis. The literature selection process was illustrated in Figure [1](#jcmm12853-fig-0001){ref-type="fig"}. All the eligible studies involved 9094 DTC cases and 12,487 controls. 13 studies (2 oesophageal cancer studies, 5 gastric cancer studies and 6 colorectal cancer studies) were identified for the *MspI* polymorphism, including a total of 1717 cases and 2046 controls. And for the *Ile/Val* polymorphism, 26 studies (11 oesophageal cancer studies, 5 gastric cancer studies and 10 colorectal cancer studies) were retrieved, covering a total of 7377 cases and 10,441 controls. More detailed charismatics about population source, ethnicity distribution, sample size, genotyping method and adjusted OR and 95% CI and adjustment of variables if available can be seen in Tables [1](#jcmm12853-tbl-0001){ref-type="table-wrap"} and [2](#jcmm12853-tbl-0002){ref-type="table-wrap"}.

![Studies identified with criteria for inclusion and exclusion.](JCMM-20-1620-g001){#jcmm12853-fig-0001}

Association of *MspI* with digestive tract cancer {#jcmm12853-sec-0008}
-------------------------------------------------

Overall, no sufficient evidence was found to support an association between increased susceptibility of DTC and *MspI* (rs4646903) polymorphism in all genetic models when all the eligible case--control studies were pooled together. Moreover, the adjusted pooled result was consistent with the crude one (data shown in Table [3](#jcmm12853-tbl-0003){ref-type="table-wrap"} and Fig. [2](#jcmm12853-fig-0002){ref-type="fig"}A for the dominant model). In subgroup analysis by cancer type, a significant association was only found between *MspI* polymorphism and elevated colorectal cancer risk (the allele contrast: OR = 1.82, 95% CI = 1.16--2.86, *P* = 0.010). However, because of unavailable adjusted data on colorectal cancer, this positive result could not be validated (Fig. S1). Stratifying for ethnicity, an increased susceptibility was found in individuals with CC genotype among Caucasians and mixed population (the codominant model: OR = 1.39, 95% CI = 1.06--1.82, *P* = 0.018; OR = 5.7, 95% CI = 1.37--23.60, *P* = 0.016 respectively). However, no evidence was observed to prove that among Asians. In the stratified analysis by the source of controls, sample size or genotyping method, some statistical correlations were observed in the group of 'population with sources unreported (NR)', 'size \<300' and 'PCR‐RFLP method' respectively (data shown in Table S1).

###### 

The overall results for *MspI* and *Ile462Val* polymorphisms in *CYP1A1* and digestive tract cancer risk

                           OR           95% CI       *P*         *I* ^2^ (%)   *Ph*    OR[a](#jcmm12853-note-0004){ref-type="fn"}   95% CI[a](#jcmm12853-note-0004){ref-type="fn"}   *P* [a](#jcmm12853-note-0004){ref-type="fn"}   *I* ^2^ (%)[a](#jcmm12853-note-0004){ref-type="fn"}   *Ph* [a](#jcmm12853-note-0004){ref-type="fn"}
  ------------- ---------- ------------ ------------ ----------- ------------- ------- -------------------------------------------- ------------------------------------------------ ---------------------------------------------- ----------------------------------------------------- -----------------------------------------------
  *MspI*                                                                                                                                                                                                                                                                                  
  Allele        C/T        1.24         0.99--1.54   0.058       59.60%        0.003   --                                           --                                               --                                                                                                   
  Dominant      CC+CT/TT   1.19         0.94--1.91   0.146       47.10%        0.030   --                                           --                                               --                                                                                                   
  Resessive     CC/CT+TT   1.32         0.80--2.17   0.283       49.50%        0.026   --                                           --                                               --                                                                                                   
  Codominant    CT/TT      1.12         0.88--1.42   0.341       42.00%        0.055   0.88                                         0.69--1.12                                       0.296                                          0.0%                                                  0.624
  CC/TT         1.30       0.80--1.21   0.296        43.50%      0.053         1.01    0.64--1.62                                   0.937                                            24.4%                                          0.265                                                 
  *Ile462Val*                                                                                                                                                                                                                                                                             
  Allele        G/A        1.24         1.09--1.41   **0.001**   69.40%        0.000   --                                           --                                               --                                                                                                   
  Dominant      GA+GG/AA   1.27         1.07--1.50   **0.006**   74.40%        0.000   --                                           --                                               --                                                                                                   
  Resessive     GG/AA+GA   1.49         1.21--1.82   **0.000**   22.30%        0.157   --                                           --                                               --                                                                                                   
  Codominant    GA/AA      1.21         1.02--1.45   **0.032**   74.20%        0.000   1.03                                         0.92--1.67                                       0.593                                          37.9%                                                 0.074
  GG/AA         1.58       1.24--2.00   **0.000**    35.40%      0.042         1.49    1.23--1.96                                   **0.005**                                        30.1%                                          0.160                                                 

Significance of bold value: *P* \< 0.05 means a significant relationship between the polymorphism and digestive tract cancer risk.

Adjusted. *Ph*:*P*‐value of Q‐test for heterogeneity identification; *I* ^2^ index: a quantitative measurement which indicates the proportion of total variation in study estimates that is due to between‐study heterogeneity.
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![(**A**) Forest plot of digestive cancer risk associated with *MspI* polymorphism (the dominant model CC + CT *versus* TT). (**B**) Forest plot of digestive cancer risk associated with *Ile/Val* polymorphism (the dominant model GA+GG *versus* AA).](JCMM-20-1620-g002){#jcmm12853-fig-0002}

Association of *Ile/Val* with digestive tract cancer {#jcmm12853-sec-0009}
----------------------------------------------------

The G allele was significantly associated with elevated DTCs risk with per‐allele OR of 1.24 (95% CI = 1.09--1.41, *P* = 0.001). Similar results were also detected under other genetic models and in our adjusted pooled result (data shown in Table [3](#jcmm12853-tbl-0003){ref-type="table-wrap"} and Fig. [2](#jcmm12853-fig-0002){ref-type="fig"}B, the dominant model). In the further subgroup analysis based on tumour type, the statistics strongly supported the significant relationship between *Ile/Val* and the chance of suffering oesophageal and colorectal cancer (the allele contrast: OR = 1.36, 95% CI = 1.19--1.56, *P* = 0.000, OR = 1.27, 95% CI = 1.01--1.61, *P* = 0.043 respectively). But the positive result was only observed in oesophagus cancer from the adjusted result partially together (Fig. S2). A significant association was also observed in Asians (the codominant model: OR = 1.62, 95% CI = 1.26--2.09, *P* = 0.000), but not in caucasians or mixed individuals. Stratified by the source of controls, significant association was observed both in HB and NR group. Stratified by sample size and genotyping method, associations were found in most groups. Detailed analyses of the genetic variant are provided in Table S2.

Heterogeneity analyses {#jcmm12853-sec-0010}
----------------------

For *MspI* polymorphism, moderate heterogeneity was detected (*e.g*. the dominant model: *I* ^2^ = 47.1%, *Ph* = 0.030). As shown in Tables S3 and S4, subgroup analyses stratified by cancer type, ethnicity, source of controls, sample size and genotyping method could not explain the source of heterogeneity at length. Hence, to further explore the heterogeneity source, we performed Galbraith graph. The study conducted by Saeed *et al*. [24](#jcmm12853-bib-0024){ref-type="ref"} may be the main source of heterogeneity (data shown in Fig. [3](#jcmm12853-fig-0003){ref-type="fig"}A). Removing this study, the result of the meta‐analysis did not change essentially (*e.g*. the dominant mode: OR = 1.10, 95% CI = 0.90--1.35, *P* = 0.336), but its heterogeneity decreased significantly (the dominant model: *I* ^2^ = 28.6%, *Ph* = 0.165) (Fig. S3). Similar results were observed in other genetic models. In the same way, we found the source of heterogeneity in Figure [3](#jcmm12853-fig-0003){ref-type="fig"}B for *Ile/Val* polymorphism. When we removed the study conducted by Pereira Serafim *et al*. [47](#jcmm12853-bib-0047){ref-type="ref"}, the heterogeneity decreased sharply, while the results remained qualitatively (the dominant mode: OR = 1.14, 95% CI = 1.03--1.27, *P* = 0.016; *I* ^2^ = 34.8%, *Ph* = 0.046) (Fig. S4).

![(**A**) Galbraith graph for *MspI* polymorphism (the dominant model CC + CT *versus* TT): the study conducted by Saeed *et al*. may be the main source of heterogeneity. (**B**) Galbraith graph for *Ile/Val* polymorphism (the dominant model GA+GG *versus* AA): the study conducted by Pereira Serafim *et al*. may be the main source of heterogeneity.](JCMM-20-1620-g003){#jcmm12853-fig-0003}

Sensitivity analyses {#jcmm12853-sec-0011}
--------------------

The corresponding pooled ORs were not qualitatively influenced when any particular study had been removed from the meta‐analysis (including the studies not conforming to HWE) for the two polymorphisms respectively (see in Fig. [4](#jcmm12853-fig-0004){ref-type="fig"}A and B). It confirmed that the results of the present meta‐analysis are reliable and stable.

![(**A**) Influence analysis of the summary odds ratio coefficients on the association between *MspI* polymorphism with digestive tract cancers risk (the dominant model CC + CT *versus* TT). Results were computed by omitting each study (left column) in turn. Bars, 95% CI. (**B**) Influence analysis of the summary odds ratio coefficients on the association between *Ile/Val* polymorphism with digestive tract cancers risk (the dominant model GA + GG *versus* AA). Results were computed by omitting each study (left column) in turn. Bars, 95% CI.](JCMM-20-1620-g004){#jcmm12853-fig-0004}

Publication Bias {#jcmm12853-sec-0012}
----------------

Begg\'s funnel plot and Egger\'s test were performed to diagnose the publication bias of papers. The shapes of the funnel plots did not reveal any evidence of obvious asymmetry in all comparison models for *MspI* (*e.g*. the dominant model in Fig. [5](#jcmm12853-fig-0005){ref-type="fig"}A). Statistically the results of both tests showed no publication bias (Begg\'s test *P* = 0.127, Egger\'s test *P* = 0.136, *t* = 1.61, 95% CI = −0.46 to 2.97). Regarding *Ile/Val*, no publication bias was detected as well in the dominant model (Begg\'s test *P* = 0.071, Egger\'s test *P* = 0.085, *t* = 1.80, 95% CI = −0.23 to 3.30) (Fig. [5](#jcmm12853-fig-0005){ref-type="fig"}B).

![(**A**) Begg\'s funnel plot for publication bias test for *MspI* polymorphism (the dominant model CC + CT *versus* TT). Each point represents a separate study for the indicated association. (**B**) Begg\'s funnel plot for publication bias test *Ile/Val* polymorphism (the dominant model GA+GG *versus* AA). Each point represents a separate study for the indicated association.](JCMM-20-1620-g005){#jcmm12853-fig-0005}

Discussion {#jcmm12853-sec-0013}
==========

CYP1A, the subfamily of Cytochrome P450, is an important phase I metabolic enzyme. As a key subtype of CYP1A, CYP1A1 is distributed widely in the kidney, lung, stomach, colon, larynx, placenta, skin, lymphocyte, brain and other tissues [14](#jcmm12853-bib-0014){ref-type="ref"}. What\'s more, recent studies have demonstrated that it involves the metabolism of some exogenous carcinogens such as PAHs. *CYP1A1* gene can promote the carcinogenic process by converting PAHs into their ultimate DNA‐binding forms [11](#jcmm12853-bib-0011){ref-type="ref"}.

*MspI* and *Ile/Val*, the main gene polymorphisms of *CYP1A1*, have been both verified associated with many kinds of cancers by large number of meta‐analyses [9](#jcmm12853-bib-0009){ref-type="ref"}. However, inconsistent results have been reported. To clarify this inconsistency, this meta‐analysis was established. To our best knowledge, it is the first one to explore the association of *CYP1A1* polymorphisms and DTC risk in the whole population. Correlation association between *CYP1A1 Ile/Val* polymorphism and DTC susceptibility were detected in our meta‐analysis. While no evidence showed the association between *CYP1A1 MspI* polymorphism and DTC risk. The overall result is consistent with that of the meta‐analysis performed by Liu *et al*. [14](#jcmm12853-bib-0014){ref-type="ref"} which was designed only in Chinese population.

Stratified by cancer type, the *MspI* CC genotype carriers were confirmed with an increased susceptibility to colorectal cancer but not to oesophageal or gastric cancer. While an A to G mutation in *Ile/Val* polymorphism increased the cancer risk in EC and CC groups. The results were partially inconsistent with Wu *et al*. [9](#jcmm12853-bib-0009){ref-type="ref"}. In fact, the studies we included in the present meta‐analysis were updated compared with Wu *et al*. And unhealthy eating habits could contribute to the digestive tract damage, such as excessive drinking. That is why different primary cancers of digestive tract may be caused by similar risk factors [13](#jcmm12853-bib-0013){ref-type="ref"}. On the other hand, DTC includes so many kinds of malignant tumours that heterogeneities among them will be found. One reason for the issue may be that the gene--gene and gene--environment interactions mechanisms differ in diverse digestive tract parts. To our common knowledge, some of the digestive tract tumours have their specific risk factors. For instance eating spicy and hot food can evaluate the risk of oesophageal cancer, whereas diet with high fat and low fibre may enhance the incidence of colorectal cancer. In addition, researchers have verified that *Helicobacter pylori* infection significantly increased susceptibility to gastric cancer [5](#jcmm12853-bib-0005){ref-type="ref"}, [6](#jcmm12853-bib-0006){ref-type="ref"}, [13](#jcmm12853-bib-0013){ref-type="ref"}, [18](#jcmm12853-bib-0018){ref-type="ref"}. In a word, the aetiological factors sensitive to various types of DTCs are not all the same. In the subgroup analysis by ethnicity, significant difference was detected in caucasian and mixed group for *MspI* polymorphism. Interestingly, high correlativity was otherwise observed in Asian group for *Ile/Val* polymorphism. This think‐provoking phenomenon may excellently reveal that genetic diversity exactly exists among various ethnicities across countrywide. Individuals, disturbing in different places of the world, will experience different environments, including climate, temperature and radiation [7](#jcmm12853-bib-0007){ref-type="ref"} and will form diverse lifestyles especially a variety of eating habits. Both of the above will contribute to the genetic background discrepancy among ethnicities. In addition, we conduct two subgroup analyses for adjusted status (Yes or no) and adjusted status especially for smoking history (Yes or no) for *Ile/Val* polymorphism. The result in every subgroup is corresponding (Table S5), which verified the reliability of our results again. As the number of studies with adjusted data for *MspI* polymorphism is only 4, and moreover, only one study provided adjusted data for smoking, we did not carry out the analyses for *MspI* polymorphism.

Some limitations and potential bias cannot be ignored in our meta‐analysis. First, we centre on the heterogeneity. Moderate and high heterogeneity were detected among the studies for *MspI* and *Ile/Val* respectively. Through Galbraith graph, we found the study conducted by Saeed *et al*. [24](#jcmm12853-bib-0024){ref-type="ref"} count for the main source of heterogeneity for *MspI*. For *Ile/Val*, the heterogeneity mainly came from study conducted by Pereira Serafim *et al*. [47](#jcmm12853-bib-0047){ref-type="ref"}. Through reviewing the two papers, we found some reasons to explain that. In the former study, the population was from Saudi Arabia and the number of case and control group is 94/79. While in the later, the population was from Brazil and the number of case and control group is 114/114. In our point, both Saudi Arabia and Brazil have vast territories and long histories. Hence, maybe the ethnic origins are complex. And the lifestyles and customs may vary significantly across the two countries, respectively, which would contribute to great heterogeneity. What is more, the sample sizes of both studies are relatively smaller. Concluding from the results of subgroup analyses, the sample size, the source of controls and the genotyping method also influence the heterogeneity in a certain degree. Thus, more studies with large enough sample sizes and more detailed criteria are warranted. Lastly, published studies were included in our studies, whereas many other unpublished data were ignored. Therefore, potentially publication bias will exist in our study.

In summary, our meta‐analysis revealed the significant association between the *CYP1A1 Ile462Val* polymorphism and increased digest tract cancers risk. While no sufficient evidence was found to support the association between the *CYP1A1 MspI* polymorphism and DTC. In the subgroup analyses, the positive results were found in CC group, caucasians and mixed individuals for *MspI* polymorphism. Our results suggest that the *CYP1A1* polymorphisms are potential risk factors for DTC. Large sample size and well‐designed studies with more clinical information like age, gender, smoking and drinking are needed to clarify our finding.
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